The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 15-day Dexcom G7 had a MARD of 8%, a small ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The Dexcom G7 15 Day ...
Dexcom reaffirmed its 2025 revenue guidance of $4.6 billion, representing 14% growth. The company also maintained its operating margin and adjusted EBITDA margin guidance at approximately 21% and 30%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results